SG11202003407VA - PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF - Google Patents

PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF

Info

Publication number
SG11202003407VA
SG11202003407VA SG11202003407VA SG11202003407VA SG11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA SG 11202003407V A SG11202003407V A SG 11202003407VA
Authority
SG
Singapore
Prior art keywords
tbk
pyrimidine
inhibitor compounds
ikke
ikke inhibitor
Prior art date
Application number
SG11202003407VA
Other languages
English (en)
Inventor
Srinivasa R Karra
Yufang Xiao
Brian A Sherer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11202003407VA publication Critical patent/SG11202003407VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202003407VA 2017-10-17 2018-10-17 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF SG11202003407VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762573251P 2017-10-17 2017-10-17
PCT/US2018/056190 WO2019079373A1 (en) 2017-10-17 2018-10-17 PYRIMIDINE TBK / IKKε INHIBITORY COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
SG11202003407VA true SG11202003407VA (en) 2020-05-28

Family

ID=64110185

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003407VA SG11202003407VA (en) 2017-10-17 2018-10-17 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF

Country Status (14)

Country Link
US (1) US20230019491A1 (enExample)
EP (1) EP3697772A1 (enExample)
JP (1) JP7266592B2 (enExample)
KR (1) KR20200072519A (enExample)
CN (1) CN111247135A (enExample)
AU (1) AU2018352699A1 (enExample)
BR (1) BR112020007466A2 (enExample)
CA (1) CA3078579A1 (enExample)
IL (1) IL273891A (enExample)
MX (1) MX2020003507A (enExample)
RU (1) RU2020115596A (enExample)
SG (1) SG11202003407VA (enExample)
TW (1) TWI802604B (enExample)
WO (1) WO2019079373A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020007549A2 (pt) * 2017-10-17 2020-09-24 Merck Patent Gmbh compostos inibidores de pirimidina tbk/ikképsilon e uso dos mesmos
JP7359783B2 (ja) 2018-06-05 2023-10-11 クリネティックス ファーマシューティカルズ,インク. メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用
CN112552280A (zh) * 2019-09-25 2021-03-26 常州强力先端电子材料有限公司 一种高产酸的磺酰亚胺类光产酸剂
EP4054583A4 (en) * 2019-11-07 2023-10-25 Crinetics Pharmaceuticals, Inc. MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND THEIR USES
MX2022007439A (es) 2019-12-18 2022-07-19 Crinetics Pharmaceuticals Inc Antagonistas de piperidina del receptor de melanocortina subtipo 2 (mc2r) sustituidos con gem y usos de los mismos.
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ,インク. スピロ環式ピペリジンメラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用
TW202302108A (zh) 2021-03-19 2023-01-16 美商克林提克斯醫藥股份有限公司 用於治療疾病之黑素皮質素亞型-2受體(mc2r)拮抗劑
CN117447407B (zh) * 2023-12-19 2024-06-11 潍坊医学院 一种JAK2抑制剂Pacritinib及其中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2911139A1 (fr) * 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CA2698511C (en) * 2007-09-04 2016-10-11 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
MX2012004313A (es) * 2009-10-12 2012-07-20 Myrexis Inc Compuestos de amino-pirimidina como inhibidores de cinasa 1 de union a tank (tbk1) y/o i-kappa-b-cinasa epsilon (ikk epsilon).
GB201012105D0 (en) * 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
AU2012242777A1 (en) * 2011-04-12 2013-10-31 Alzheimer's Institute Of America, Inc. Compositions and therapeutic uses of IKK-related kinase epsilon and TANKbinding kinase 1 inhibitors
DE102011112978A1 (de) * 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
RU2018102685A (ru) * 2015-06-29 2019-08-02 Мерк Патент Гмбх СОЕДИНЕНИЯ-ИНГИБИТОРЫ TBK/IKKε И ИХ ПРИМЕНЕНИЕ

Also Published As

Publication number Publication date
MX2020003507A (es) 2020-07-22
BR112020007466A2 (pt) 2020-09-24
AU2018352699A1 (en) 2020-05-28
EP3697772A1 (en) 2020-08-26
JP2020537671A (ja) 2020-12-24
KR20200072519A (ko) 2020-06-22
RU2020115596A3 (enExample) 2021-11-18
IL273891A (en) 2020-05-31
RU2020115596A (ru) 2021-11-18
JP7266592B2 (ja) 2023-04-28
CN111247135A (zh) 2020-06-05
US20230019491A1 (en) 2023-01-19
CA3078579A1 (en) 2019-04-25
WO2019079373A1 (en) 2019-04-25
TWI802604B (zh) 2023-05-21
TW201922735A (zh) 2019-06-16

Similar Documents

Publication Publication Date Title
HUS2400019I1 (hu) KRas G12C inhibotorok
ZA201707641B (en) Tbk/ikke inhibitor compounds and uses thereof
IL273236A (en) Pyrazolopyrimidine compounds and their uses
SG11202003407VA (en) PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
LT3630761T (lt) Kras g12c inhibitoriai ir jų naudojimo būdai
IL270330B (en) Beta-lactamase inhibitors and their uses
SG10201913927VA (en) Kinase inhibitors and uses thereof
GB201605126D0 (en) Inhibitors and their uses
GB201714745D0 (en) New compounds and uses
PT3357922T (pt) Composto de pirimidina ou piridopiridona e sua aplicação
EP3131877A4 (en) Guanidine compounds and use thereof
PT3543240T (pt) Inibidor de urat1 e utilização deste
IL263949A (en) Complement inhibitors and their uses
GB201714734D0 (en) New compounds and uses
SI3621694T1 (sl) Zaviralci lrrc33 in njihove uporabe
GB201714740D0 (en) New compounds and uses
SG11202004877UA (en) Sulfonamide compounds and use thereof
ZA201901773B (en) Pde4 inhibitor
IL262400A (en) Erbb inhibitors and uses thereof
GB201714736D0 (en) New compounds and uses
IL247921A0 (en) Glutaminase inhibitor compounds, preparations containing them and their uses
GB201712110D0 (en) New compounds and uses
ZA201803212B (en) Gelatinase inhibitors and use thereof
ZA202002825B (en) Pyrimidine τβκ/ικκε inhibitor compounds and uses thereof
IL265617B (en) 1-phenylpropanone compounds and their use